June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
The anti-angiogenic effect of tectorigenin in a mouse model of retinopathy of prematurity
Author Affiliations & Notes
  • Kui Dong Kang
    Ophthalmology, Catholic Univ of Korea, Incheon, Korea (the Republic of)
  • Kyung-A Kim
    Funtional Food Center, Korea Institute of Science and Technology, Gangneung, Korea (the Republic of)
  • Sang Hoon Jung
    Funtional Food Center, Korea Institute of Science and Technology, Gangneung, Korea (the Republic of)
  • Su Ah Kim
    Ophthalmology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships Kui Dong Kang, None; Kyung-A Kim, None; Sang Hoon Jung, None; Su Ah Kim, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 202. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kui Dong Kang, Kyung-A Kim, Sang Hoon Jung, Su Ah Kim; The anti-angiogenic effect of tectorigenin in a mouse model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):202.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Tectorigenin is an isoflavone derived from the rhizome of Belamacanda chinensis. In this study, oxygen-induced retinopathy was used to characterize the anti-angiogenic properties of tectorigenin in mice.

Methods: ICR neonatal mice were exposed to 75% oxygen from postnatal day (P)7 until P12 and returned to room air (21% oxygen) for five days (P12 to P17). Mice were subjected to daily intraperitoneal injection of tectorigenin (1 mg/kg, 10 mg/kg) and vehicle from P12 to P17. Retro-orbital injection of FITC-dextran was performed and retinal flat mounts were viewed by fluorescence microscopy. Central avascular area was quantified from the digital images in a masked fashion using image analysis software (NIH ImageJ). Neovascular tufts were quantified by using SWIFT_NV and neovascular lumens were quantified from histologic section in a masked fashion. Immunohistochemistry and Western blot analysis were also performed to demonstrate the anti-angiogenic activity of this compound in vivo.

Results: In the retina of tectorigenin injected mouse (10mg/kg), the central non-perfusion area was significantly decreased compared to the vehicle injected group (1.76±0.5 mm2 vs 2.85±0.6 mm2, P<0.05). In vehicle-injected group, 33.45 ± 5.51% of the total retinal area was avascular, whereas the retinas of pups treated with high-dose (10 mg/kg) tectorigenin showed avascular retinal areas of 21.25 ±4.34% (P<0.05). High dose of tectorigenin also significantly reduced the number of vascular lumens in the histologic section. Tectorigenin (10 mg/kg) significantly reduced the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2), MMP-9, and angiotensin II compared to the vehicle injected group. Tectorigenin did not affect CD31 abundance at any tested dose.

Conclusions: Our results show that tectorigenin possesses powerful anti-angiogenic properties and can attenuates new vessel formation in the retina after systemic administration. These results implies that this compound can be considered as a candidate substance for therapeutic inhibition of retinal angiogenesis.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×